Cargando…

Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors

Insufficient intratumoral T-cell infiltration and lack of tumor-specific immune surveillance in tumor microenvironment (TME) hinder the progression of cancer immunotherapy. In this study, we explored a recombinant vaccinia virus encoding an EpCAM BiTE (VV-EpCAM BiTE) to modulate the immune suppressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Min, Zuo, Shuguang, Chen, Zhimin, Qian, Peng, Zhang, Yenan, Kong, Lingkai, Gao, Honglan, Wei, Jiwu, Dong, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702515/ https://www.ncbi.nlm.nih.gov/pubmed/36451817 http://dx.doi.org/10.3389/fimmu.2022.1017574

Ejemplares similares

The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015)

Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors
por: Hanauer, Jan RH, et al.
Publicado: (2016)

Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas
por: Fong, Dominic, et al.
Publicado: (2014)

Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
por: Herrmann, Ines, et al.
Publicado: (2010)

Expression of EpCAM in uveal melanoma
por: Odashiro, Danilo N, et al.
Publicado: (2006)

Biology and clinical relevance of EpCAM
por: Keller, Laura, et al.
Publicado: (2019)

EpCAM as Modulator of Tissue Plasticity
por: Fagotto, François
Publicado: (2020)

EpCAM(high) and EpCAM(low) circulating tumor cells in metastatic prostate and breast cancer patients
por: de Wit, Sanne, et al.
Publicado: (2018)

Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)
por: Zuo, Shuguang, et al.
Publicado: (2021)

EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex
por: Subramanian, Nithya, et al.
Publicado: (2015)

An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
por: Zuo, Shuguang, et al.
Publicado: (2021)

Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma
por: Salnikov, Alexei V, et al.
Publicado: (2009)

CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager
por: Bagheri, Andisheh, et al.
Publicado: (2022)

Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110
por: Deisting, Wibke, et al.
Publicado: (2015)

Current View on EpCAM Structural Biology
por: Gaber, Aljaž, et al.
Publicado: (2020)

Evolution of Thyroglobulin Loop Kinetics in EpCAM
por: Chen, Serena H., et al.
Publicado: (2021)

EpCAM expression in squamous cell carcinoma of the uterine cervix detected by monoclonal antibody to the membrane-proximal part of EpCAM
por: Chantima, Warangkana, et al.
Publicado: (2017)

Correction to: EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex
por: Subramanian, Nithya, et al.
Publicado: (2020)

EpCAM Knockdown Alters MicroRNA Expression in Retinoblastoma- Functional Implication of EpCAM Regulated MiRNA in Tumor Progression
por: Beta, Madhu, et al.
Publicado: (2014)

Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth
por: Zheng, Jingying, et al.
Publicado: (2017)

IgG-like Bispecific Antibody CD3×EpCAM Generated by Split Intein Against Colorectal Cancer
por: Wang, Lei, et al.
Publicado: (2022)

A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer
por: Ploeg, Emily Maria, et al.
Publicado: (2023)

EpCAM proteolysis: new fragments with distinct functions?
por: Schnell, Ulrike, et al.
Publicado: (2013)

EpCAM and the biology of hepatic stem/progenitor cells
por: Dollé, Laurent, et al.
Publicado: (2014)

Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma
por: Armeanu-Ebinger, Sorin, et al.
Publicado: (2013)

Functions of EpCAM in physiological processes and diseases (Review)
por: Huang, Li, et al.
Publicado: (2018)

Revisiting the Roles of Pro-Metastatic EpCAM in Cancer
por: Mohtar, M. Aiman, et al.
Publicado: (2020)

Correction: EpCAM Knockdown Alters MicroRNA Expression in Retinoblastoma- Functional Implication of EpCAM Regulated MiRNA in Tumor Progression
Publicado: (2015)

Distinct EpCAM-Positive Stem Cell Niches Are Engaged in Chronic and Neoplastic Liver Diseases
por: Safarikia, Samira, et al.
Publicado: (2020)

An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer
por: Liao, Mei-Ying, et al.
Publicado: (2015)

Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines
por: Schönberger, Stefan, et al.
Publicado: (2020)

EpCAM (CD326) finding its role in cancer
por: Baeuerle, P A, et al.
Publicado: (2007)

EpCAM (CD326) finding its role in cancer
por: Baeuerle, P A, et al.
Publicado: (2007)

Expression of EpCam and Villin in Barrett’s Esophagus and in Gastric Cardia
por: Anders, Mario, et al.
Publicado: (2008)

Selection and targeting of EpCAM protein by ssDNA aptamer
por: Alshaer, Walhan, et al.
Publicado: (2017)

EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs
por: Macdonald, Joanna, et al.
Publicado: (2018)

Clinicopathology of EpCAM and EGFR in Human Epithelial Ovarian Carcinoma
por: Zheng, Jingying, et al.
Publicado: (2017)

EpCAM(low) Circulating Tumor Cells: Gold in the Waste
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

EpCAM tumor specificity and proteoform patterns in urothelial cancer
por: Dressler, Franz F., et al.
Publicado: (2023)

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
por: Xu, Tianqi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ad0b3qomtrjro24e33rbbirvl2